PKM and early-onset autosomal dominant Alzheimer disease: Studies indicate that CFA is an Nrf2 anti-oxidative agonist (Dong et al. 2020; Kim et al. 2016; Chen et al. 2015) and PKM2 modulator in an Alzheimer’s disease model (Dong et al. 2020), depicting its anti-oxidative and metabolic properties.